Ever Supreme Bio Technology Co., Ltd is a regenerative medicine company focused on the research and development of stem cell and cancer immunotherapy drugs. The company develops cell-based therapeutics through a patented technology platform, with key products including CAR001, a CAR-T therapy for solid tumors that has completed Phase I safety validation and entered Phase IIa clinical trials, and EXO-001. Its operations involve clinical trials and the production of cell preparations, targeting the global market for precision medicine and advanced cancer treatments. The company collaborates with international medical institutions, including Mayo Clinic, and participates in major biotechnology exhibitions to showcase its R&D progress.

Summarised from the company's own disclosures

Industry Biotechnology Homepage ever-supreme.com.tw
Sector Healthcare IR page —
Tags
regenerative medicine, stem cell therapy, cancer immunotherapy, car-t therapy, cell-based therapeutics, precision medicine, clinical trials, CAR001, EXO-001
Press page —

Metrics

Valuation  
Market cap NT$ 13.667B
Market cap (USD) $ 414.825M
P/E 28.45
PEG 0.99
P/BV 4.69
P/S 11.99
P/OCF 31.04
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 25.9%
ROI 28.1%
ROIC 23.6%
Profit margin 42.2%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 28.9%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 12.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 1.018B 933.813M 758.391M 627.512M 438.841M 70.597M 10.819M 0 —
Net profit 429.432M 367.251M 539.397M 200.714M 369.601M -106.829M -94.219M -68.771M -30.602M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 164 — — — — — — — —
P/S 14.12 — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

【2026長海盃路跑熱力登場!長聖生技、中亞聯大暨醫療體系與各衍生企業超過6,000人為愛、為健康、為幸福而跑】
「2026長海盃路跑」 由中國醫藥大學附設醫院主辦,中醫大及亞大暨醫療體系與衍生企業共同協辦,吸引超過6,000名同仁與眷屬熱情參與,共同展現跨機構團隊凝聚力與健康活力!
中國醫藥大學暨醫療體系董事長、亞洲大學暨醫療體系創辦人蔡長海親自帶領各機構領導團隊、同仁及家屬共襄盛舉,傳遞「愛、健康、幸福」的活動理念。
蔡長海董事長表示,體系中的醫療同仁平時忙於照顧病人,也希望大家在照顧別人的同時,別忘了照顧自己,和家人一起養成規律運動的習慣,讓同仁與家屬有機會定期相聚、一起運動。
精彩開幕|音樂與活力交織
九天民俗技藝團以鼓陣及大旗演出揭開序幕,中醫大附醫交響樂團攜手28位護理師組成的活力啦啦隊及優秀歌手,共同演繹專為本次活動創作的《長海之歌》,展現醫療團隊的多元才華!
健康開跑|10K挑戰、3K健康同樂
知名有氧健身老師潘若迪帶領全場暖身,鼓勵大家走出戶外、養成運動習慣。活動設有10公里挑戰組及3公里健康組,讓同仁與眷屬一起享受運動樂趣。
親子嘉年華|歡樂不間斷
LINE FRIENDS人氣角色熊大、兔兔及莎莉驚喜現身!現場還有「元氣小英雄」健康闖關、創意彩繪區、14輛特色胖卡餐車及元氣補給站,讓活動充滿親子同樂的歡樂氣氛。
從守護病人健康,到關懷每位同仁
長聖生技持續重視員工身心健康與幸福職場,透過運動、藝術及多元交流,讓健康與幸福融入日常生活,也凝聚體系共同向前的力量。
為愛而跑、為健康而跑、為幸福而跑!










 

back

Copyright © 長聖國際生技股份有限公司 All Rights Reserved. 網站製作:新視野網頁設計

Official Website

Linkedin

TOP

Language

長聖生技拓展國際連結,強化與世界頂尖醫療機構的交流,此次由范揚政教授邀請梅約診所 (Mayo Clinic) Shauna Overgaard博士於9月29日蒞臨參訪。Overgaard博士現任梅約診所人工智慧策略與架構資深總監、AI驗證與治理計畫共同主任,致力於推動AI研究走向臨床應用。此次長聖劉銖淇董事長帶領團隊以創新研發技術的進度與發展做雙邊的深度交流,為長聖生技帶來兼具策略與實務的國際視野。


back

Copyright © 長聖國際生技股份有限公司 All Rights Reserved. 網站製作:新視野網頁設計

Official Website

Linkedin

TOP

Language

Prompts

Ever Supreme Bio Technology Co., Ltd (ticker 6712.TWO), listed in Taiwan.

ETFs Holding Ever Supreme Bio Technology Co., Ltd

ETF Weight in ETF Shares Market value As of
AVEE 0.03% 7,663 $ 33.11K Nov 16, 2026
DEXC 0.01% 8,399 $ 37.066K Nov 12, 2026
DFEV 0.01% 38,000 $ 167.7K Nov 12, 2026
DFEM 0.00% 64,993 $ 286.825K Nov 12, 2026
DFSE 0.00% 3,579 $ 15.795K Nov 12, 2026
DFAE 0.00% 36,961 $ 163.115K Nov 12, 2026
DFAX 0.00% 34,238 $ 151.098K Nov 12, 2026
AVEM 0.00% 11,000 $ 47.529K Nov 16, 2026